Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyFludiazepam
Identification
- Name
- Fludiazepam
- Accession Number
- DB01567
- Type
- Small Molecule
- Groups
- Approved, Illicit
- Description
Fludiazepam is a drug which is a benzodiazepine derivative. It possesses anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant properties. It is a scheduled drug in the U.S., but is approved for use in Japan.
- Structure
Structure for DB01567 (Fludiazepam)
- Synonyms
- 7-chloro-5-(O-Fluorophenyl)-1,3-dihydro-1-methyl-2H-1,4-benzodiazepin-2-one
- Erispan
- Fludiazepamum
- International/Other Brands
- Erispan (Sumitomo)
- Categories
- Anti-Anxiety Agents
- Benzazepines
- Benzodiazepines and benzodiazepine derivatives
- Benzodiazepinones
- Central Nervous System Agents
- Central Nervous System Depressants
- Muscle Relaxants
- Muscle Relaxants, Centrally Acting Agents
- Nervous System
- Neuromuscular Agents
- Peripheral Nervous System Agents
- Psycholeptics
- Psychotropic Drugs
- Tranquilizing Agents
- UNII
- 7F64A2K16Z
- CAS number
- 3900-31-0
- Weight
- Average: 302.731
Monoisotopic: 302.062218928 - Chemical Formula
- C16H12ClFN2O
- InChI Key
- ROYOYTLGDLIGBX-UHFFFAOYSA-N
- InChI
- InChI=1S/C16H12ClFN2O/c1-20-14-7-6-10(17)8-12(14)16(19-9-15(20)21)11-4-2-3-5-13(11)18/h2-8H,9H2,1H3
- IUPAC Name
- 7-chloro-5-(2-fluorophenyl)-1-methyl-2,3-dihydro-1H-1,4-benzodiazepin-2-one
- SMILES
- CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F
Pharmacology
- Indication
Used for the short-term treatment of anxiety disorders.
- Pharmacodynamics
Fludiazepam is a benzodiazepine derivative. It possesses anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant properties. Fludiazepam accumulates primarily in the cortex and thalamus.
- Mechanism of action
Fludiazepam has similar action to diazepam, but binds with four times more affinity to benzodiazepine receptors than diazepam.
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
Hepatic.
- Route of elimination
- Not Available
- Half life
- Not Available
- Clearance
- Not Available
- Toxicity
Symptoms of overdose include drowsiness, weakness, nausea, dizziness, abdominal pain, cerebral oedema and renal tubular necrosis, hyperglycaemia and hypoglycaemia, liver damage, encephalopathy, coma and death.
- Affected organisms
- Humans and other mammals
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group 7-Nitroindazole The risk or severity of adverse effects can be increased when Fludiazepam is combined with 7-Nitroindazole. Experimental Acepromazine The risk or severity of adverse effects can be increased when Fludiazepam is combined with Acepromazine. Approved, Vet Approved Aceprometazine The risk or severity of adverse effects can be increased when Fludiazepam is combined with Aceprometazine. Approved Adipiplon The risk or severity of adverse effects can be increased when Fludiazepam is combined with Adipiplon. Investigational Agomelatine The risk or severity of adverse effects can be increased when Fludiazepam is combined with Agomelatine. Approved, Investigational Alaproclate The risk or severity of adverse effects can be increased when Fludiazepam is combined with Alaproclate. Experimental Alfaxalone The risk or severity of adverse effects can be increased when Fludiazepam is combined with Alfaxalone. Vet Approved Alfentanil The risk or severity of adverse effects can be increased when Alfentanil is combined with Fludiazepam. Approved, Illicit Allopregnanolone The risk or severity of adverse effects can be increased when Fludiazepam is combined with Allopregnanolone. Investigational Alphacetylmethadol The risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Fludiazepam. Experimental, Illicit Alphaprodine The risk or severity of adverse effects can be increased when Fludiazepam is combined with Alphaprodine. Illicit Alprazolam The risk or severity of adverse effects can be increased when Alprazolam is combined with Fludiazepam. Approved, Illicit, Investigational Ambroxol acefyllinate The therapeutic efficacy of Fludiazepam can be decreased when used in combination with Ambroxol acefyllinate. Experimental, Investigational Amikacin The risk or severity of adverse effects can be increased when Fludiazepam is combined with Amikacin. Approved, Investigational, Vet Approved Aminophylline The therapeutic efficacy of Fludiazepam can be decreased when used in combination with Aminophylline. Approved Amisulpride The risk or severity of adverse effects can be increased when Fludiazepam is combined with Amisulpride. Approved, Investigational Amitriptyline The risk or severity of adverse effects can be increased when Amitriptyline is combined with Fludiazepam. Approved Amobarbital The risk or severity of adverse effects can be increased when Amobarbital is combined with Fludiazepam. Approved, Illicit Amoxapine The risk or severity of adverse effects can be increased when Amoxapine is combined with Fludiazepam. Approved Amperozide The risk or severity of adverse effects can be increased when Fludiazepam is combined with Amperozide. Experimental Aripiprazole The risk or severity of adverse effects can be increased when Aripiprazole is combined with Fludiazepam. Approved, Investigational Articaine The risk or severity of adverse effects can be increased when Fludiazepam is combined with Articaine. Approved Asenapine The risk or severity of adverse effects can be increased when Asenapine is combined with Fludiazepam. Approved Azaperone The risk or severity of adverse effects can be increased when Fludiazepam is combined with Azaperone. Investigational, Vet Approved Azelastine Fludiazepam may increase the central nervous system depressant (CNS depressant) activities of Azelastine. Approved Baclofen The risk or severity of adverse effects can be increased when Baclofen is combined with Fludiazepam. Approved Barbital The risk or severity of adverse effects can be increased when Barbital is combined with Fludiazepam. Illicit Benperidol The risk or severity of adverse effects can be increased when Fludiazepam is combined with Benperidol. Approved, Investigational Benzphetamine The risk or severity of adverse effects can be increased when Fludiazepam is combined with Benzphetamine. Approved, Illicit Benzyl alcohol The risk or severity of adverse effects can be increased when Fludiazepam is combined with Benzyl alcohol. Approved Brexpiprazole The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Fludiazepam. Approved, Investigational Brimonidine Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Fludiazepam. Approved Bromazepam The risk or severity of adverse effects can be increased when Bromazepam is combined with Fludiazepam. Approved, Illicit, Investigational Bromisoval The risk or severity of adverse effects can be increased when Fludiazepam is combined with Bromisoval. Experimental Bromperidol The risk or severity of adverse effects can be increased when Fludiazepam is combined with Bromperidol. Approved, Investigational Brompheniramine The risk or severity of adverse effects can be increased when Brompheniramine is combined with Fludiazepam. Approved Brotizolam The risk or severity of adverse effects can be increased when Fludiazepam is combined with Brotizolam. Approved, Investigational, Withdrawn Bupivacaine The risk or severity of adverse effects can be increased when Bupivacaine is combined with Fludiazepam. Approved, Investigational Buprenorphine Fludiazepam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Approved, Illicit, Investigational, Vet Approved Bupropion The risk or severity of adverse effects can be increased when Fludiazepam is combined with Bupropion. Approved Buspirone The risk or severity of adverse effects can be increased when Buspirone is combined with Fludiazepam. Approved, Investigational Butabarbital The risk or severity of adverse effects can be increased when Butabarbital is combined with Fludiazepam. Approved, Illicit Butacaine The risk or severity of adverse effects can be increased when Fludiazepam is combined with Butacaine. Vet Approved Butalbital The risk or severity of adverse effects can be increased when Butalbital is combined with Fludiazepam. Approved, Illicit Butamben The risk or severity of adverse effects can be increased when Fludiazepam is combined with Butamben. Approved, Withdrawn Butethal The risk or severity of adverse effects can be increased when Butethal is combined with Fludiazepam. Approved, Illicit Butorphanol The risk or severity of adverse effects can be increased when Butorphanol is combined with Fludiazepam. Approved, Illicit, Vet Approved Caffeine The therapeutic efficacy of Fludiazepam can be decreased when used in combination with Caffeine. Approved Canertinib The risk or severity of adverse effects can be increased when Fludiazepam is combined with Canertinib. Investigational Carbamazepine The risk or severity of adverse effects can be increased when Carbamazepine is combined with Fludiazepam. Approved, Investigational Carbinoxamine The risk or severity of adverse effects can be increased when Carbinoxamine is combined with Fludiazepam. Approved Carfentanil The risk or severity of adverse effects can be increased when Carfentanil is combined with Fludiazepam. Illicit, Investigational, Vet Approved Carisoprodol The risk or severity of adverse effects can be increased when Carisoprodol is combined with Fludiazepam. Approved Cetirizine The risk or severity of adverse effects can be increased when Cetirizine is combined with Fludiazepam. Approved Chloral hydrate The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Fludiazepam. Approved, Illicit, Investigational, Vet Approved Chlordiazepoxide The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Fludiazepam. Approved, Illicit, Investigational Chlormezanone The risk or severity of adverse effects can be increased when Chlormezanone is combined with Fludiazepam. Approved, Investigational, Withdrawn Chloroprocaine The risk or severity of adverse effects can be increased when Chloroprocaine is combined with Fludiazepam. Approved Chlorphenamine The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Fludiazepam. Approved Chlorpromazine The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Fludiazepam. Approved, Investigational, Vet Approved Chlorprothixene The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Fludiazepam. Approved, Investigational, Withdrawn Chlorzoxazone The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Fludiazepam. Approved Cinchocaine The risk or severity of adverse effects can be increased when Cinchocaine is combined with Fludiazepam. Approved, Vet Approved Citalopram The risk or severity of adverse effects can be increased when Fludiazepam is combined with Citalopram. Approved Clemastine The risk or severity of adverse effects can be increased when Clemastine is combined with Fludiazepam. Approved, Investigational Clidinium The risk or severity of adverse effects can be increased when Clidinium is combined with Fludiazepam. Approved Clindamycin The risk or severity of adverse effects can be increased when Fludiazepam is combined with Clindamycin. Approved, Vet Approved Clobazam The risk or severity of adverse effects can be increased when Clobazam is combined with Fludiazepam. Approved, Illicit clomethiazole The risk or severity of adverse effects can be increased when Fludiazepam is combined with clomethiazole. Investigational Clomipramine The risk or severity of adverse effects can be increased when Clomipramine is combined with Fludiazepam. Approved, Investigational, Vet Approved Clonazepam The risk or severity of adverse effects can be increased when Clonazepam is combined with Fludiazepam. Approved, Illicit Clonidine The risk or severity of adverse effects can be increased when Clonidine is combined with Fludiazepam. Approved Clopenthixol The risk or severity of adverse effects can be increased when Fludiazepam is combined with Clopenthixol. Experimental Clorazepate The risk or severity of adverse effects can be increased when Clorazepate is combined with Fludiazepam. Approved, Illicit Clothiapine The risk or severity of adverse effects can be increased when Fludiazepam is combined with Clothiapine. Experimental Clozapine The risk or severity of adverse effects can be increased when Fludiazepam is combined with Clozapine. Approved Cocaine The risk or severity of adverse effects can be increased when Cocaine is combined with Fludiazepam. Approved, Illicit Codeine The risk or severity of adverse effects can be increased when Codeine is combined with Fludiazepam. Approved, Illicit Cyclizine The risk or severity of adverse effects can be increased when Cyclizine is combined with Fludiazepam. Approved Cyclobenzaprine The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Fludiazepam. Approved Cyclopropane The risk or severity of adverse effects can be increased when Fludiazepam is combined with Cyclopropane. Experimental Cyclosporine The risk or severity of adverse effects can be increased when Fludiazepam is combined with Cyclosporine. Approved, Investigational, Vet Approved Cyproheptadine The risk or severity of adverse effects can be increased when Cyproheptadine is combined with Fludiazepam. Approved Dantrolene The risk or severity of adverse effects can be increased when Dantrolene is combined with Fludiazepam. Approved, Investigational Dapiprazole The risk or severity of adverse effects can be increased when Dapiprazole is combined with Fludiazepam. Approved Dapoxetine The risk or severity of adverse effects can be increased when Fludiazepam is combined with Dapoxetine. Investigational Deramciclane The risk or severity of adverse effects can be increased when Fludiazepam is combined with Deramciclane. Investigational Desflurane The risk or severity of adverse effects can be increased when Desflurane is combined with Fludiazepam. Approved Desipramine The risk or severity of adverse effects can be increased when Desipramine is combined with Fludiazepam. Approved, Investigational Desloratadine The risk or severity of adverse effects can be increased when Desloratadine is combined with Fludiazepam. Approved, Investigational Desvenlafaxine The risk or severity of adverse effects can be increased when Fludiazepam is combined with Desvenlafaxine. Approved, Investigational Detomidine The risk or severity of adverse effects can be increased when Fludiazepam is combined with Detomidine. Vet Approved Dexbrompheniramine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Fludiazepam. Approved Dexmedetomidine The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Fludiazepam. Approved, Vet Approved Dextromoramide The risk or severity of adverse effects can be increased when Dextromoramide is combined with Fludiazepam. Experimental, Illicit Dextropropoxyphene The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Fludiazepam. Approved, Illicit, Investigational, Withdrawn Diazepam The risk or severity of adverse effects can be increased when Diazepam is combined with Fludiazepam. Approved, Illicit, Investigational, Vet Approved Diethyl ether The risk or severity of adverse effects can be increased when Fludiazepam is combined with Diethyl ether. Experimental Difenoxin The risk or severity of adverse effects can be increased when Difenoxin is combined with Fludiazepam. Approved, Illicit Dihydrocodeine The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Fludiazepam. Approved, Illicit Dihydroetorphine The risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Fludiazepam. Experimental, Illicit Dihydromorphine The risk or severity of adverse effects can be increased when Dihydromorphine is combined with Fludiazepam. Experimental, Illicit Dimenhydrinate The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Fludiazepam. Approved Diphenhydramine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Fludiazepam. Approved, Investigational Diphenoxylate The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Fludiazepam. Approved, Illicit Dixyrazine The risk or severity of adverse effects can be increased when Fludiazepam is combined with Dixyrazine. Experimental Doramectin The risk or severity of adverse effects can be increased when Fludiazepam is combined with Doramectin. Vet Approved Dotarizine The risk or severity of adverse effects can be increased when Fludiazepam is combined with Dotarizine. Investigational Doxepin The risk or severity of adverse effects can be increased when Doxepin is combined with Fludiazepam. Approved, Investigational Doxofylline The serum concentration of Doxofylline can be decreased when it is combined with Fludiazepam. Approved, Investigational Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Fludiazepam. Approved, Vet Approved DPDPE The risk or severity of adverse effects can be increased when Fludiazepam is combined with DPDPE. Experimental Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Fludiazepam. Approved, Illicit Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Fludiazepam. Approved, Vet Approved Drotebanol The risk or severity of adverse effects can be increased when Drotebanol is combined with Fludiazepam. Experimental, Illicit Duloxetine The risk or severity of adverse effects can be increased when Fludiazepam is combined with Duloxetine. Approved Dyclonine The risk or severity of adverse effects can be increased when Dyclonine is combined with Fludiazepam. Approved Dyphylline The therapeutic efficacy of Fludiazepam can be decreased when used in combination with Dyphylline. Approved Ecgonine The risk or severity of adverse effects can be increased when Ecgonine is combined with Fludiazepam. Experimental, Illicit Ecopipam The risk or severity of adverse effects can be increased when Fludiazepam is combined with Ecopipam. Investigational Efavirenz The risk or severity of adverse effects can be increased when Efavirenz is combined with Fludiazepam. Approved, Investigational Eltanolone The risk or severity of adverse effects can be increased when Fludiazepam is combined with Eltanolone. Investigational Enflurane The risk or severity of adverse effects can be increased when Enflurane is combined with Fludiazepam. Approved, Investigational, Vet Approved Entacapone The risk or severity of adverse effects can be increased when Entacapone is combined with Fludiazepam. Approved, Investigational Eperisone The risk or severity of adverse effects can be increased when Fludiazepam is combined with Eperisone. Approved, Investigational Escitalopram The risk or severity of adverse effects can be increased when Fludiazepam is combined with Escitalopram. Approved, Investigational Estazolam The risk or severity of adverse effects can be increased when Estazolam is combined with Fludiazepam. Approved, Illicit Eszopiclone The risk or severity of adverse effects can be increased when Eszopiclone is combined with Fludiazepam. Approved, Investigational Ethanol Fludiazepam may increase the central nervous system depressant (CNS depressant) activities of Ethanol. Approved Ethchlorvynol The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Fludiazepam. Approved, Illicit, Withdrawn Ethosuximide The risk or severity of adverse effects can be increased when Ethosuximide is combined with Fludiazepam. Approved Ethotoin The risk or severity of adverse effects can be increased when Ethotoin is combined with Fludiazepam. Approved Ethyl carbamate The risk or severity of adverse effects can be increased when Fludiazepam is combined with Ethyl carbamate. Withdrawn Ethyl chloride The risk or severity of adverse effects can be increased when Fludiazepam is combined with Ethyl chloride. Approved, Experimental, Investigational Ethyl loflazepate The risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Fludiazepam. Approved, Illicit Ethylmorphine The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Fludiazepam. Approved, Illicit Etidocaine The risk or severity of adverse effects can be increased when Fludiazepam is combined with Etidocaine. Approved Etifoxine The risk or severity of adverse effects can be increased when Fludiazepam is combined with Etifoxine. Investigational, Withdrawn Etizolam The risk or severity of adverse effects can be increased when Fludiazepam is combined with Etizolam. Approved Etomidate The risk or severity of adverse effects can be increased when Etomidate is combined with Fludiazepam. Approved Etoperidone The risk or severity of adverse effects can be increased when Fludiazepam is combined with Etoperidone. Withdrawn Etorphine The risk or severity of adverse effects can be increased when Etorphine is combined with Fludiazepam. Illicit, Vet Approved Ezogabine The risk or severity of adverse effects can be increased when Ezogabine is combined with Fludiazepam. Approved, Investigational Felbamate The risk or severity of adverse effects can be increased when Felbamate is combined with Fludiazepam. Approved Fencamfamine The risk or severity of adverse effects can be increased when Fencamfamine is combined with Fludiazepam. Approved, Illicit, Withdrawn Fentanyl The risk or severity of adverse effects can be increased when Fentanyl is combined with Fludiazepam. Approved, Illicit, Investigational, Vet Approved Fexofenadine The risk or severity of adverse effects can be increased when Fexofenadine is combined with Fludiazepam. Approved, Investigational Flibanserin The risk or severity of adverse effects can be increased when Flibanserin is combined with Fludiazepam. Approved, Investigational Fluanisone The risk or severity of adverse effects can be increased when Fludiazepam is combined with Fluanisone. Experimental Flunarizine The risk or severity of adverse effects can be increased when Flunarizine is combined with Fludiazepam. Approved Flunitrazepam The risk or severity of adverse effects can be increased when Flunitrazepam is combined with Fludiazepam. Approved, Illicit Fluoxetine The risk or severity of adverse effects can be increased when Fludiazepam is combined with Fluoxetine. Approved, Vet Approved Flupentixol The risk or severity of adverse effects can be increased when Flupentixol is combined with Fludiazepam. Approved, Investigational, Withdrawn Fluphenazine The risk or severity of adverse effects can be increased when Fluphenazine is combined with Fludiazepam. Approved Flurazepam The risk or severity of adverse effects can be increased when Flurazepam is combined with Fludiazepam. Approved, Illicit, Investigational Fluspirilene The risk or severity of adverse effects can be increased when Fludiazepam is combined with Fluspirilene. Approved, Investigational Fluticasone propionate The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Fludiazepam. Approved Fluvoxamine The risk or severity of adverse effects can be increased when Fludiazepam is combined with Fluvoxamine. Approved, Investigational Fosphenytoin The serum concentration of Fosphenytoin can be increased when it is combined with Fludiazepam. Approved, Investigational Fospropofol The risk or severity of adverse effects can be increased when Fludiazepam is combined with Fospropofol. Approved, Illicit, Investigational Gabapentin The risk or severity of adverse effects can be increased when Gabapentin is combined with Fludiazepam. Approved, Investigational Gabapentin Enacarbil The risk or severity of adverse effects can be increased when Gabapentin Enacarbil is combined with Fludiazepam. Approved, Investigational Gamma Hydroxybutyric Acid The risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Fludiazepam. Approved, Illicit, Investigational Ganciclovir The therapeutic efficacy of Fludiazepam can be decreased when used in combination with Ganciclovir. Approved, Investigational Gepirone The risk or severity of adverse effects can be increased when Fludiazepam is combined with Gepirone. Investigational Glutethimide The risk or severity of adverse effects can be increased when Glutethimide is combined with Fludiazepam. Approved, Illicit Guanfacine The risk or severity of adverse effects can be increased when Guanfacine is combined with Fludiazepam. Approved, Investigational Halazepam The risk or severity of adverse effects can be increased when Halazepam is combined with Fludiazepam. Approved, Illicit, Withdrawn Haloperidol The risk or severity of adverse effects can be increased when Haloperidol is combined with Fludiazepam. Approved Halothane The risk or severity of adverse effects can be increased when Halothane is combined with Fludiazepam. Approved, Vet Approved Heroin The risk or severity of adverse effects can be increased when Heroin is combined with Fludiazepam. Approved, Illicit, Investigational Hexobarbital The risk or severity of adverse effects can be increased when Hexobarbital is combined with Fludiazepam. Approved Hyaluronidase The therapeutic efficacy of Fludiazepam can be decreased when used in combination with Hyaluronidase. Approved, Investigational Hydrocodone Fludiazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. Approved, Illicit Hydromorphone The risk or severity of adverse effects can be increased when Hydromorphone is combined with Fludiazepam. Approved, Illicit Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Fludiazepam. Approved Iloperidone The risk or severity of adverse effects can be increased when Iloperidone is combined with Fludiazepam. Approved Imipramine The risk or severity of adverse effects can be increased when Imipramine is combined with Fludiazepam. Approved Indalpine The risk or severity of adverse effects can be increased when Fludiazepam is combined with Indalpine. Investigational, Withdrawn Indiplon The risk or severity of adverse effects can be increased when Fludiazepam is combined with Indiplon. Investigational Isocarboxazid The therapeutic efficacy of Fludiazepam can be increased when used in combination with Isocarboxazid. Approved Isoflurane The risk or severity of adverse effects can be increased when Isoflurane is combined with Fludiazepam. Approved, Vet Approved Ketamine The risk or severity of adverse effects can be increased when Ketamine is combined with Fludiazepam. Approved, Vet Approved Ketazolam The risk or severity of adverse effects can be increased when Fludiazepam is combined with Ketazolam. Approved Ketobemidone The risk or severity of adverse effects can be increased when Fludiazepam is combined with Ketobemidone. Approved, Investigational Lamotrigine The risk or severity of adverse effects can be increased when Lamotrigine is combined with Fludiazepam. Approved, Investigational Levetiracetam The risk or severity of adverse effects can be increased when Levetiracetam is combined with Fludiazepam. Approved, Investigational Levobupivacaine The risk or severity of adverse effects can be increased when Levobupivacaine is combined with Fludiazepam. Approved, Investigational Levocabastine The risk or severity of adverse effects can be increased when Fludiazepam is combined with Levocabastine. Approved, Investigational Levocetirizine The risk or severity of adverse effects can be increased when Levocetirizine is combined with Fludiazepam. Approved Levodopa The risk or severity of adverse effects can be increased when Levodopa is combined with Fludiazepam. Approved Levomethadyl Acetate The risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Fludiazepam. Approved, Investigational Levomilnacipran The risk or severity of adverse effects can be increased when Fludiazepam is combined with Levomilnacipran. Approved, Investigational Levorphanol The risk or severity of adverse effects can be increased when Levorphanol is combined with Fludiazepam. Approved Lithium cation The risk or severity of adverse effects can be increased when Lithium is combined with Fludiazepam. Experimental Lofentanil The risk or severity of adverse effects can be increased when Fludiazepam is combined with Lofentanil. Illicit Lofexidine The therapeutic efficacy of Fludiazepam can be increased when used in combination with Lofexidine. Approved, Investigational Loprazolam The risk or severity of adverse effects can be increased when Fludiazepam is combined with Loprazolam. Experimental Loratadine The risk or severity of adverse effects can be increased when Loratadine is combined with Fludiazepam. Approved, Investigational Lorazepam The risk or severity of adverse effects can be increased when Lorazepam is combined with Fludiazepam. Approved Lormetazepam The risk or severity of adverse effects can be increased when Fludiazepam is combined with Lormetazepam. Approved Lorpiprazole The serum concentration of Fludiazepam can be increased when it is combined with Lorpiprazole. Approved Loxapine The risk or severity of adverse effects can be increased when Loxapine is combined with Fludiazepam. Approved Lurasidone The risk or severity of adverse effects can be increased when Lurasidone is combined with Fludiazepam. Approved, Investigational Magnesium carbonate The risk or severity of adverse effects can be increased when Fludiazepam is combined with Magnesium carbonate. Approved, Investigational Magnesium citrate The risk or severity of adverse effects can be increased when Fludiazepam is combined with Magnesium citrate. Approved Magnesium hydroxide The risk or severity of adverse effects can be increased when Fludiazepam is combined with Magnesium hydroxide. Approved, Investigational Magnesium sulfate The therapeutic efficacy of Fludiazepam can be increased when used in combination with Magnesium sulfate. Approved, Investigational, Vet Approved Magnesium Trisilicate The risk or severity of adverse effects can be increased when Fludiazepam is combined with Magnesium Trisilicate. Approved Maprotiline The risk or severity of adverse effects can be increased when Maprotiline is combined with Fludiazepam. Approved, Investigational Mebicar The risk or severity of adverse effects can be increased when Fludiazepam is combined with Mebicar. Experimental Meclizine The risk or severity of adverse effects can be increased when Meclizine is combined with Fludiazepam. Approved Medazepam The risk or severity of adverse effects can be increased when Fludiazepam is combined with Medazepam. Experimental Medetomidine The risk or severity of adverse effects can be increased when Fludiazepam is combined with Medetomidine. Vet Approved Mefloquine The therapeutic efficacy of Fludiazepam can be decreased when used in combination with Mefloquine. Approved, Investigational Melatonin The risk or severity of adverse effects can be increased when Melatonin is combined with Fludiazepam. Approved, Nutraceutical, Vet Approved Melperone The risk or severity of adverse effects can be increased when Fludiazepam is combined with Melperone. Approved, Investigational Mepivacaine The risk or severity of adverse effects can be increased when Mepivacaine is combined with Fludiazepam. Approved, Vet Approved Meprobamate The risk or severity of adverse effects can be increased when Meprobamate is combined with Fludiazepam. Approved, Illicit Meptazinol The risk or severity of adverse effects can be increased when Fludiazepam is combined with Meptazinol. Experimental Mesoridazine The risk or severity of adverse effects can be increased when Mesoridazine is combined with Fludiazepam. Approved, Investigational Metaxalone The risk or severity of adverse effects can be increased when Metaxalone is combined with Fludiazepam. Approved Methadone Fludiazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone. Approved Methadyl Acetate The risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Fludiazepam. Approved, Illicit Methapyrilene The risk or severity of adverse effects can be increased when Fludiazepam is combined with Methapyrilene. Withdrawn Methaqualone The risk or severity of adverse effects can be increased when Fludiazepam is combined with Methaqualone. Illicit, Withdrawn Methocarbamol The risk or severity of adverse effects can be increased when Methocarbamol is combined with Fludiazepam. Approved, Vet Approved Methohexital The risk or severity of adverse effects can be increased when Methohexital is combined with Fludiazepam. Approved Methotrimeprazine Fludiazepam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. Approved, Investigational Methoxyflurane The risk or severity of adverse effects can be increased when Methoxyflurane is combined with Fludiazepam. Approved, Investigational, Vet Approved Methsuximide The risk or severity of adverse effects can be increased when Methsuximide is combined with Fludiazepam. Approved Methylecgonine The risk or severity of adverse effects can be increased when Fludiazepam is combined with Methylecgonine. Experimental Methylphenobarbital The risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Fludiazepam. Approved Metyrosine Fludiazepam may increase the sedative activities of Metyrosine. Approved Mianserin The therapeutic efficacy of Fludiazepam can be decreased when used in combination with Mianserin. Approved, Investigational Midazolam The risk or severity of adverse effects can be increased when Midazolam is combined with Fludiazepam. Approved, Illicit Milnacipran The risk or severity of adverse effects can be increased when Fludiazepam is combined with Milnacipran. Approved, Investigational Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Fludiazepam. Approved, Investigational Mirtazapine Fludiazepam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. Approved Molindone The risk or severity of adverse effects can be increased when Fludiazepam is combined with Molindone. Approved Morphine The risk or severity of adverse effects can be increased when Morphine is combined with Fludiazepam. Approved, Investigational Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Fludiazepam. Approved, Investigational Nalbuphine The risk or severity of adverse effects can be increased when Nalbuphine is combined with Fludiazepam. Approved Nefazodone The risk or severity of adverse effects can be increased when Fludiazepam is combined with Nefazodone. Approved, Withdrawn Neomycin The risk or severity of adverse effects can be increased when Fludiazepam is combined with Neomycin. Approved, Vet Approved Nitrazepam The risk or severity of adverse effects can be increased when Nitrazepam is combined with Fludiazepam. Approved Nitrous oxide The risk or severity of adverse effects can be increased when Nitrous oxide is combined with Fludiazepam. Approved, Vet Approved Nordazepam The risk or severity of adverse effects can be increased when Fludiazepam is combined with Nordazepam. Approved Norflurane The risk or severity of adverse effects can be increased when Fludiazepam is combined with Norflurane. Approved, Investigational Normethadone The risk or severity of adverse effects can be increased when Fludiazepam is combined with Normethadone. Approved, Illicit Nortriptyline The risk or severity of adverse effects can be increased when Nortriptyline is combined with Fludiazepam. Approved Olanzapine The risk or severity of adverse effects can be increased when Fludiazepam is combined with Olanzapine. Approved, Investigational Olopatadine The risk or severity of adverse effects can be increased when Olopatadine is combined with Fludiazepam. Approved Ondansetron The risk or severity of adverse effects can be increased when Ondansetron is combined with Fludiazepam. Approved Opium The risk or severity of adverse effects can be increased when Fludiazepam is combined with Opium. Approved, Illicit Orlistat The serum concentration of Fludiazepam can be decreased when it is combined with Orlistat. Approved, Investigational Orphenadrine Fludiazepam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. Approved Osanetant The risk or severity of adverse effects can be increased when Fludiazepam is combined with Osanetant. Investigational Oxazepam The risk or severity of adverse effects can be increased when Oxazepam is combined with Fludiazepam. Approved Oxprenolol The risk or severity of adverse effects can be increased when Fludiazepam is combined with Oxprenolol. Approved Oxybuprocaine The risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Fludiazepam. Approved, Investigational Oxycodone The risk or severity of adverse effects can be increased when Oxycodone is combined with Fludiazepam. Approved, Illicit, Investigational Oxymorphone The risk or severity of adverse effects can be increased when Oxymorphone is combined with Fludiazepam. Approved, Investigational, Vet Approved Paliperidone The risk or severity of adverse effects can be increased when Paliperidone is combined with Fludiazepam. Approved Paraldehyde Fludiazepam may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. Approved, Investigational Paromomycin The risk or severity of adverse effects can be increased when Fludiazepam is combined with Paromomycin. Approved, Investigational Paroxetine The risk or severity of adverse effects can be increased when Fludiazepam is combined with Paroxetine. Approved, Investigational Penfluridol The risk or severity of adverse effects can be increased when Fludiazepam is combined with Penfluridol. Experimental Pentazocine The risk or severity of adverse effects can be increased when Pentazocine is combined with Fludiazepam. Approved, Vet Approved Pentobarbital The risk or severity of adverse effects can be increased when Pentobarbital is combined with Fludiazepam. Approved, Investigational, Vet Approved Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Fludiazepam. Approved Perazine The risk or severity of adverse effects can be increased when Fludiazepam is combined with Perazine. Approved, Investigational Perospirone The risk or severity of adverse effects can be increased when Fludiazepam is combined with Perospirone. Approved Perphenazine The risk or severity of adverse effects can be increased when Perphenazine is combined with Fludiazepam. Approved Pethidine The risk or severity of adverse effects can be increased when Pethidine is combined with Fludiazepam. Approved Phenazocine The risk or severity of adverse effects can be increased when Fludiazepam is combined with Phenazocine. Experimental Phenibut The risk or severity of adverse effects can be increased when Fludiazepam is combined with Phenibut. Experimental Phenobarbital The risk or severity of adverse effects can be increased when Phenobarbital is combined with Fludiazepam. Approved, Investigational Phenoperidine The risk or severity of adverse effects can be increased when Fludiazepam is combined with Phenoperidine. Experimental Phenoxyethanol The risk or severity of adverse effects can be increased when Fludiazepam is combined with Phenoxyethanol. Approved Phenytoin The serum concentration of Phenytoin can be increased when it is combined with Fludiazepam. Approved, Vet Approved Pimozide The risk or severity of adverse effects can be increased when Pimozide is combined with Fludiazepam. Approved Pipamperone The risk or severity of adverse effects can be increased when Fludiazepam is combined with Pipamperone. Approved, Investigational Pipotiazine The risk or severity of adverse effects can be increased when Pipotiazine is combined with Fludiazepam. Approved, Investigational Piritramide The risk or severity of adverse effects can be increased when Fludiazepam is combined with Piritramide. Approved, Investigational Pizotifen The risk or severity of adverse effects can be increased when Pizotifen is combined with Fludiazepam. Approved Polymyxin B Sulfate The risk or severity of adverse effects can be increased when Fludiazepam is combined with Polymyxin B Sulfate. Approved, Vet Approved Pomalidomide The risk or severity of adverse effects can be increased when Pomalidomide is combined with Fludiazepam. Approved Pramipexole Fludiazepam may increase the sedative activities of Pramipexole. Approved, Investigational Prazepam The risk or severity of adverse effects can be increased when Fludiazepam is combined with Prazepam. Approved, Illicit Pregabalin The therapeutic efficacy of Fludiazepam can be increased when used in combination with Pregabalin. Approved, Illicit, Investigational Prilocaine The risk or severity of adverse effects can be increased when Prilocaine is combined with Fludiazepam. Approved Primidone The risk or severity of adverse effects can be increased when Primidone is combined with Fludiazepam. Approved, Vet Approved Procaine The risk or severity of adverse effects can be increased when Procaine is combined with Fludiazepam. Approved, Investigational, Vet Approved Prochlorperazine The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Fludiazepam. Approved, Vet Approved Promazine The risk or severity of adverse effects can be increased when Promazine is combined with Fludiazepam. Approved, Vet Approved Promethazine The risk or severity of adverse effects can be increased when Promethazine is combined with Fludiazepam. Approved, Investigational Propanidid The risk or severity of adverse effects can be increased when Fludiazepam is combined with Propanidid. Experimental Proparacaine The risk or severity of adverse effects can be increased when Proparacaine is combined with Fludiazepam. Approved, Vet Approved Propofol The risk or severity of adverse effects can be increased when Propofol is combined with Fludiazepam. Approved, Investigational, Vet Approved Propoxycaine The risk or severity of adverse effects can be increased when Fludiazepam is combined with Propoxycaine. Approved Protriptyline The risk or severity of adverse effects can be increased when Protriptyline is combined with Fludiazepam. Approved Proxibarbal The risk or severity of adverse effects can be increased when Fludiazepam is combined with Proxibarbal. Experimental PSD502 The risk or severity of adverse effects can be increased when Fludiazepam is combined with PSD502. Investigational Pseudoephedrine The risk or severity of adverse effects can be increased when Fludiazepam is combined with Pseudoephedrine. Approved Pyrantel The risk or severity of adverse effects can be increased when Fludiazepam is combined with Pyrantel. Approved, Vet Approved Quazepam The risk or severity of adverse effects can be increased when Quazepam is combined with Fludiazepam. Approved, Illicit Quetiapine The risk or severity of adverse effects can be increased when Quetiapine is combined with Fludiazepam. Approved Quinisocaine The risk or severity of adverse effects can be increased when Fludiazepam is combined with Quinisocaine. Experimental Raclopride The risk or severity of adverse effects can be increased when Fludiazepam is combined with Raclopride. Investigational Ramelteon The risk or severity of adverse effects can be increased when Ramelteon is combined with Fludiazepam. Approved, Investigational Remifentanil The risk or severity of adverse effects can be increased when Remifentanil is combined with Fludiazepam. Approved Remoxipride The risk or severity of adverse effects can be increased when Remoxipride is combined with Fludiazepam. Approved, Withdrawn Reserpine The risk or severity of adverse effects can be increased when Reserpine is combined with Fludiazepam. Approved, Investigational Risperidone The risk or severity of adverse effects can be increased when Risperidone is combined with Fludiazepam. Approved, Investigational Ritanserin The risk or severity of adverse effects can be increased when Fludiazepam is combined with Ritanserin. Investigational Rizatriptan The risk or severity of adverse effects can be increased when Fludiazepam is combined with Rizatriptan. Approved Romifidine The risk or severity of adverse effects can be increased when Fludiazepam is combined with Romifidine. Vet Approved Ropinirole Fludiazepam may increase the sedative activities of Ropinirole. Approved, Investigational Ropivacaine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Fludiazepam. Approved Rotigotine Fludiazepam may increase the sedative activities of Rotigotine. Approved Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Fludiazepam. Approved Scopolamine The risk or severity of adverse effects can be increased when Scopolamine is combined with Fludiazepam. Approved, Investigational Secobarbital The risk or severity of adverse effects can be increased when Secobarbital is combined with Fludiazepam. Approved, Vet Approved Sepranolone The risk or severity of adverse effects can be increased when Fludiazepam is combined with Sepranolone. Investigational Sertindole The risk or severity of adverse effects can be increased when Fludiazepam is combined with Sertindole. Approved, Investigational, Withdrawn Sertraline The risk or severity of adverse effects can be increased when Fludiazepam is combined with Sertraline. Approved Sevoflurane The risk or severity of adverse effects can be increased when Sevoflurane is combined with Fludiazepam. Approved, Vet Approved Sodium oxybate Fludiazepam may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. Approved Stiripentol The risk or severity of adverse effects can be increased when Stiripentol is combined with Fludiazepam. Approved Sufentanil The risk or severity of adverse effects can be increased when Sufentanil is combined with Fludiazepam. Approved, Investigational Sulpiride The risk or severity of adverse effects can be increased when Sulpiride is combined with Fludiazepam. Approved, Investigational Sultopride The risk or severity of adverse effects can be increased when Fludiazepam is combined with Sultopride. Experimental Sumatriptan The risk or severity of adverse effects can be increased when Fludiazepam is combined with Sumatriptan. Approved, Investigational Suvorexant Fludiazepam may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. Approved, Investigational Tandospirone The risk or severity of adverse effects can be increased when Fludiazepam is combined with Tandospirone. Investigational Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Fludiazepam. Approved Tasimelteon The risk or severity of adverse effects can be increased when Tasimelteon is combined with Fludiazepam. Approved, Investigational Teduglutide The serum concentration of Fludiazepam can be increased when it is combined with Teduglutide. Approved Temazepam The risk or severity of adverse effects can be increased when Temazepam is combined with Fludiazepam. Approved, Investigational Tetrabenazine The risk or severity of adverse effects can be increased when Tetrabenazine is combined with Fludiazepam. Approved, Investigational Tetracaine The risk or severity of adverse effects can be increased when Fludiazepam is combined with Tetracaine. Approved, Vet Approved Tetracycline The risk or severity of adverse effects can be increased when Fludiazepam is combined with Tetracycline. Approved, Vet Approved Tetrahydropalmatine The risk or severity of adverse effects can be increased when Fludiazepam is combined with Tetrahydropalmatine. Investigational Tetrodotoxin The risk or severity of adverse effects can be increased when Fludiazepam is combined with Tetrodotoxin. Investigational Thalidomide Fludiazepam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. Approved, Investigational, Withdrawn Theophylline The therapeutic efficacy of Fludiazepam can be decreased when used in combination with Theophylline. Approved Thiamylal The risk or severity of adverse effects can be increased when Thiamylal is combined with Fludiazepam. Approved, Vet Approved Thiopental The risk or severity of adverse effects can be increased when Thiopental is combined with Fludiazepam. Approved, Vet Approved Thioridazine The risk or severity of adverse effects can be increased when Thioridazine is combined with Fludiazepam. Approved, Withdrawn Thiothixene The risk or severity of adverse effects can be increased when Thiothixene is combined with Fludiazepam. Approved Tiagabine The risk or severity of adverse effects can be increased when Tiagabine is combined with Fludiazepam. Approved, Investigational Tiapride The risk or severity of adverse effects can be increased when Fludiazepam is combined with Tiapride. Approved, Investigational Tiletamine The risk or severity of adverse effects can be increased when Fludiazepam is combined with Tiletamine. Vet Approved Tilidine The risk or severity of adverse effects can be increased when Fludiazepam is combined with Tilidine. Experimental Tizanidine The risk or severity of adverse effects can be increased when Tizanidine is combined with Fludiazepam. Approved, Investigational Tolcapone The risk or severity of adverse effects can be increased when Tolcapone is combined with Fludiazepam. Approved, Withdrawn Topiramate The risk or severity of adverse effects can be increased when Topiramate is combined with Fludiazepam. Approved Tramadol The risk or severity of adverse effects can be increased when Tramadol is combined with Fludiazepam. Approved, Investigational Tranylcypromine The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Fludiazepam. Approved, Investigational Trazodone The risk or severity of adverse effects can be increased when Trazodone is combined with Fludiazepam. Approved, Investigational Triazolam The risk or severity of adverse effects can be increased when Triazolam is combined with Fludiazepam. Approved, Investigational Tricaine methanesulfonate The risk or severity of adverse effects can be increased when Fludiazepam is combined with Tricaine methanesulfonate. Vet Approved Trichloroethylene The risk or severity of adverse effects can be increased when Fludiazepam is combined with Trichloroethylene. Approved Trifluoperazine The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Fludiazepam. Approved, Investigational Trifluperidol The risk or severity of adverse effects can be increased when Fludiazepam is combined with Trifluperidol. Experimental Triflupromazine The risk or severity of adverse effects can be increased when Triflupromazine is combined with Fludiazepam. Approved, Vet Approved Trimethadione The risk or severity of adverse effects can be increased when Fludiazepam is combined with Trimethadione. Approved Trimipramine The risk or severity of adverse effects can be increased when Trimipramine is combined with Fludiazepam. Approved Triprolidine The risk or severity of adverse effects can be increased when Triprolidine is combined with Fludiazepam. Approved Valaciclovir The therapeutic efficacy of Fludiazepam can be decreased when used in combination with Valaciclovir. Approved, Investigational Valproic Acid The risk or severity of adverse effects can be increased when Valproic Acid is combined with Fludiazepam. Approved, Investigational Vancomycin The risk or severity of adverse effects can be increased when Fludiazepam is combined with Vancomycin. Approved Vecuronium The risk or severity of adverse effects can be increased when Fludiazepam is combined with Vecuronium. Approved Venlafaxine The risk or severity of adverse effects can be increased when Fludiazepam is combined with Venlafaxine. Approved Veralipride The risk or severity of adverse effects can be increased when Fludiazepam is combined with Veralipride. Experimental Vigabatrin The risk or severity of adverse effects can be increased when Vigabatrin is combined with Fludiazepam. Approved Vinpocetine The risk or severity of adverse effects can be increased when Fludiazepam is combined with Vinpocetine. Investigational Vinyl ether The risk or severity of adverse effects can be increased when Fludiazepam is combined with Vinyl ether. Experimental Vortioxetine The risk or severity of adverse effects can be increased when Fludiazepam is combined with Vortioxetine. Approved, Investigational Xenon The risk or severity of adverse effects can be increased when Fludiazepam is combined with Xenon. Experimental Xylazine The risk or severity of adverse effects can be increased when Fludiazepam is combined with Xylazine. Vet Approved Yohimbine The therapeutic efficacy of Fludiazepam can be decreased when used in combination with Yohimbine. Approved, Investigational, Vet Approved Zaleplon The risk or severity of adverse effects can be increased when Zaleplon is combined with Fludiazepam. Approved, Illicit, Investigational Ziconotide The risk or severity of adverse effects can be increased when Ziconotide is combined with Fludiazepam. Approved Zimelidine The risk or severity of adverse effects can be increased when Fludiazepam is combined with Zimelidine. Withdrawn Ziprasidone The risk or severity of adverse effects can be increased when Ziprasidone is combined with Fludiazepam. Approved Zolazepam The risk or severity of adverse effects can be increased when Fludiazepam is combined with Zolazepam. Vet Approved Zolmitriptan The risk or severity of adverse effects can be increased when Fludiazepam is combined with Zolmitriptan. Approved, Investigational Zolpidem Fludiazepam may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. Approved Zonisamide The risk or severity of adverse effects can be increased when Zonisamide is combined with Fludiazepam. Approved, Investigational Zopiclone The risk or severity of adverse effects can be increased when Zopiclone is combined with Fludiazepam. Approved Zotepine The risk or severity of adverse effects can be increased when Fludiazepam is combined with Zotepine. Approved, Investigational, Withdrawn Zuclopenthixol The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Fludiazepam. Approved, Investigational - Food Interactions
- Avoid alcohol.
- Avoid excessive quantities of coffee or tea (Caffeine).
- Avoid taking with grapefruit juice.
References
- Synthesis Reference
Yamamato, H., Inaba, S.,Okamoto, T., Hirohashi, T., Ishizumi, K., Yamamoto, M., Maruyama, l., Mori, K. and Kobayashi, T.; U.S. Patents 3,723,461; March 27, 1973; 3,828,027; August 6, 1974 and 3,925,364; December 9, 1975; all assigned to Sumitomo Chemical Co., Ltd.
- General References
- Ishiwata K, Yanai K, Ido T, Miura-Kanno Y, Kawashima K: Synthesis and biodistribution of [11C]fludiazepam for imaging benzodiazepine receptors. Int J Rad Appl Instrum B. 1988;15(4):365-71. [PubMed:2855634]
- Nakatsuka I, Shimizu H, Asami Y, Katoh T, Hirose A, Yoshitake A: Benzodiazepines and their metabolites: relationship between binding affinity to the benzodiazepine receptor and pharmacological activity. Life Sci. 1985 Jan 14;36(2):113-9. [PubMed:2857046]
- External Links
- Human Metabolome Database
- HMDB0015513
- KEGG Drug
- D01354
- PubChem Compound
- 3369
- PubChem Substance
- 46507563
- ChemSpider
- 3252
- ChEBI
- 31618
- ChEMBL
- CHEMBL13291
- Therapeutic Targets Database
- DAP000934
- PharmGKB
- PA164745609
- Wikipedia
- Fludiazepam
- ATC Codes
- N05BA17 — Fludiazepam
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 218.5-219 Yamamato, H., Inaba, S.,Okamoto, T., Hirohashi, T., Ishizumi, K., Yamamoto, M., Maruyama, l., Mori, K. and Kobayashi, T.; U.S. Patents 3,723,461; March 27, 1973; 3,828,027; August 6, 1974 and 3,925,364; December 9, 1975; all assigned to Sumitomo Chemical Co., Ltd. logP 2.75 HANSCH,C ET AL. (1995) - Predicted Properties
Property Value Source Water Solubility 0.0144 mg/mL ALOGPS logP 2.83 ALOGPS logP 3.22 ChemAxon logS -4.3 ALOGPS pKa (Strongest Basic) 1.89 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 2 ChemAxon Hydrogen Donor Count 0 ChemAxon Polar Surface Area 32.67 Å2 ChemAxon Rotatable Bond Count 1 ChemAxon Refractivity 80.03 m3·mol-1 ChemAxon Polarizability 29.45 Å3 ChemAxon Number of Rings 3 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule Yes ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 1.0 Blood Brain Barrier + 0.9946 Caco-2 permeable + 0.8567 P-glycoprotein substrate Substrate 0.6618 P-glycoprotein inhibitor I Inhibitor 0.5293 P-glycoprotein inhibitor II Non-inhibitor 0.8532 Renal organic cation transporter Inhibitor 0.592 CYP450 2C9 substrate Non-substrate 0.6724 CYP450 2D6 substrate Non-substrate 0.9087 CYP450 3A4 substrate Substrate 0.8081 CYP450 1A2 substrate Inhibitor 0.7925 CYP450 2C9 inhibitor Non-inhibitor 0.5446 CYP450 2D6 inhibitor Non-inhibitor 0.8884 CYP450 2C19 inhibitor Inhibitor 0.5598 CYP450 3A4 inhibitor Inhibitor 0.5153 CYP450 inhibitory promiscuity High CYP Inhibitory Promiscuity 0.5827 Ames test Non AMES toxic 0.8792 Carcinogenicity Non-carcinogens 0.817 Biodegradation Not ready biodegradable 1.0 Rat acute toxicity 2.2719 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9953 hERG inhibition (predictor II) Non-inhibitor 0.8236
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Mass Spectrum (Electron Ionization) MS splash10-0uk9-2794000000-6f1a3e2e0783b2069f2f Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as 1,4-benzodiazepines. These are organic compounds containing a benzene ring fused to a 1,4-azepine.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Benzodiazepines
- Sub Class
- 1,4-benzodiazepines
- Direct Parent
- 1,4-benzodiazepines
- Alternative Parents
- Alpha amino acids and derivatives / Fluorobenzenes / Aryl fluorides / Aryl chlorides / Tertiary carboxylic acid amides / Lactams / Ketimines / Propargyl-type 1,3-dipolar organic compounds / Azacyclic compounds / Organopnictogen compounds show 5 more
- Substituents
- 1,4-benzodiazepine / Alpha-amino acid or derivatives / Fluorobenzene / Halobenzene / Aryl chloride / Aryl fluoride / Aryl halide / Monocyclic benzene moiety / Benzenoid / Tertiary carboxylic acid amide show 20 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- organofluorine compound, organochlorine compound, 1,4-benzodiazepinone (CHEBI:31618)
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Potentiator
- General Function
- Inhibitory extracellular ligand-gated ion channel activity
- Specific Function
- Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...
- Gene Name
- GABRA1
- Uniprot ID
- P14867
- Uniprot Name
- Gamma-aminobutyric acid receptor subunit alpha-1
- Molecular Weight
- 51801.395 Da
References
- Nakatsuka I, Shimizu H, Asami Y, Katoh T, Hirose A, Yoshitake A: Benzodiazepines and their metabolites: relationship between binding affinity to the benzodiazepine receptor and pharmacological activity. Life Sci. 1985 Jan 14;36(2):113-9. [PubMed:2857046]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Potentiator
- General Function
- Inhibitory extracellular ligand-gated ion channel activity
- Specific Function
- GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
- Gene Name
- GABRA2
- Uniprot ID
- P47869
- Uniprot Name
- Gamma-aminobutyric acid receptor subunit alpha-2
- Molecular Weight
- 51325.85 Da
References
- Nakatsuka I, Shimizu H, Asami Y, Katoh T, Hirose A, Yoshitake A: Benzodiazepines and their metabolites: relationship between binding affinity to the benzodiazepine receptor and pharmacological activity. Life Sci. 1985 Jan 14;36(2):113-9. [PubMed:2857046]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Potentiator
- General Function
- Inhibitory extracellular ligand-gated ion channel activity
- Specific Function
- GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
- Gene Name
- GABRA3
- Uniprot ID
- P34903
- Uniprot Name
- Gamma-aminobutyric acid receptor subunit alpha-3
- Molecular Weight
- 55164.055 Da
References
- Nakatsuka I, Shimizu H, Asami Y, Katoh T, Hirose A, Yoshitake A: Benzodiazepines and their metabolites: relationship between binding affinity to the benzodiazepine receptor and pharmacological activity. Life Sci. 1985 Jan 14;36(2):113-9. [PubMed:2857046]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Potentiator
- General Function
- Transporter activity
- Specific Function
- GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
- Gene Name
- GABRA5
- Uniprot ID
- P31644
- Uniprot Name
- Gamma-aminobutyric acid receptor subunit alpha-5
- Molecular Weight
- 52145.645 Da
References
- Nakatsuka I, Shimizu H, Asami Y, Katoh T, Hirose A, Yoshitake A: Benzodiazepines and their metabolites: relationship between binding affinity to the benzodiazepine receptor and pharmacological activity. Life Sci. 1985 Jan 14;36(2):113-9. [PubMed:2857046]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Potentiator
- General Function
- Inhibitory extracellular ligand-gated ion channel activity
- Specific Function
- GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
- Gene Name
- GABRG1
- Uniprot ID
- Q8N1C3
- Uniprot Name
- Gamma-aminobutyric acid receptor subunit gamma-1
- Molecular Weight
- 53594.49 Da
References
- Nakatsuka I, Shimizu H, Asami Y, Katoh T, Hirose A, Yoshitake A: Benzodiazepines and their metabolites: relationship between binding affinity to the benzodiazepine receptor and pharmacological activity. Life Sci. 1985 Jan 14;36(2):113-9. [PubMed:2857046]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Potentiator
- General Function
- Inhibitory extracellular ligand-gated ion channel activity
- Specific Function
- Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...
- Gene Name
- GABRG2
- Uniprot ID
- P18507
- Uniprot Name
- Gamma-aminobutyric acid receptor subunit gamma-2
- Molecular Weight
- 54161.78 Da
References
- Nakatsuka I, Shimizu H, Asami Y, Katoh T, Hirose A, Yoshitake A: Benzodiazepines and their metabolites: relationship between binding affinity to the benzodiazepine receptor and pharmacological activity. Life Sci. 1985 Jan 14;36(2):113-9. [PubMed:2857046]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Potentiator
- General Function
- Inhibitory extracellular ligand-gated ion channel activity
- Specific Function
- GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
- Gene Name
- GABRG3
- Uniprot ID
- Q99928
- Uniprot Name
- Gamma-aminobutyric acid receptor subunit gamma-3
- Molecular Weight
- 54288.16 Da
References
- Nakatsuka I, Shimizu H, Asami Y, Katoh T, Hirose A, Yoshitake A: Benzodiazepines and their metabolites: relationship between binding affinity to the benzodiazepine receptor and pharmacological activity. Life Sci. 1985 Jan 14;36(2):113-9. [PubMed:2857046]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Potentiator
- General Function
- Ligand-gated ion channel activity
- Specific Function
- Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...
- Gene Name
- GABRB1
- Uniprot ID
- P18505
- Uniprot Name
- Gamma-aminobutyric acid receptor subunit beta-1
- Molecular Weight
- 54234.085 Da
References
- Nakatsuka I, Shimizu H, Asami Y, Katoh T, Hirose A, Yoshitake A: Benzodiazepines and their metabolites: relationship between binding affinity to the benzodiazepine receptor and pharmacological activity. Life Sci. 1985 Jan 14;36(2):113-9. [PubMed:2857046]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Potentiator
- General Function
- Inhibitory extracellular ligand-gated ion channel activity
- Specific Function
- Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...
- Gene Name
- GABRB2
- Uniprot ID
- P47870
- Uniprot Name
- Gamma-aminobutyric acid receptor subunit beta-2
- Molecular Weight
- 59149.895 Da
References
- Nakatsuka I, Shimizu H, Asami Y, Katoh T, Hirose A, Yoshitake A: Benzodiazepines and their metabolites: relationship between binding affinity to the benzodiazepine receptor and pharmacological activity. Life Sci. 1985 Jan 14;36(2):113-9. [PubMed:2857046]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Potentiator
- General Function
- Gaba-gated chloride ion channel activity
- Specific Function
- Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...
- Gene Name
- GABRB3
- Uniprot ID
- P28472
- Uniprot Name
- Gamma-aminobutyric acid receptor subunit beta-3
- Molecular Weight
- 54115.04 Da
References
- Nakatsuka I, Shimizu H, Asami Y, Katoh T, Hirose A, Yoshitake A: Benzodiazepines and their metabolites: relationship between binding affinity to the benzodiazepine receptor and pharmacological activity. Life Sci. 1985 Jan 14;36(2):113-9. [PubMed:2857046]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Potentiator
- General Function
- Gaba-a receptor activity
- Specific Function
- GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
- Gene Name
- GABRD
- Uniprot ID
- O14764
- Uniprot Name
- Gamma-aminobutyric acid receptor subunit delta
- Molecular Weight
- 50707.835 Da
References
- Nakatsuka I, Shimizu H, Asami Y, Katoh T, Hirose A, Yoshitake A: Benzodiazepines and their metabolites: relationship between binding affinity to the benzodiazepine receptor and pharmacological activity. Life Sci. 1985 Jan 14;36(2):113-9. [PubMed:2857046]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Potentiator
- General Function
- Inhibitory extracellular ligand-gated ion channel activity
- Specific Function
- GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
- Gene Name
- GABRE
- Uniprot ID
- P78334
- Uniprot Name
- Gamma-aminobutyric acid receptor subunit epsilon
- Molecular Weight
- 57971.175 Da
References
- Nakatsuka I, Shimizu H, Asami Y, Katoh T, Hirose A, Yoshitake A: Benzodiazepines and their metabolites: relationship between binding affinity to the benzodiazepine receptor and pharmacological activity. Life Sci. 1985 Jan 14;36(2):113-9. [PubMed:2857046]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Potentiator
- General Function
- Gaba-a receptor activity
- Specific Function
- GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. In the ute...
- Gene Name
- GABRP
- Uniprot ID
- O00591
- Uniprot Name
- Gamma-aminobutyric acid receptor subunit pi
- Molecular Weight
- 50639.735 Da
References
- Nakatsuka I, Shimizu H, Asami Y, Katoh T, Hirose A, Yoshitake A: Benzodiazepines and their metabolites: relationship between binding affinity to the benzodiazepine receptor and pharmacological activity. Life Sci. 1985 Jan 14;36(2):113-9. [PubMed:2857046]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Potentiator
- General Function
- Gaba-a receptor activity
- Specific Function
- GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. Rho-1 GABA...
- Gene Name
- GABRR1
- Uniprot ID
- P24046
- Uniprot Name
- Gamma-aminobutyric acid receptor subunit rho-1
- Molecular Weight
- 55882.91 Da
References
- Nakatsuka I, Shimizu H, Asami Y, Katoh T, Hirose A, Yoshitake A: Benzodiazepines and their metabolites: relationship between binding affinity to the benzodiazepine receptor and pharmacological activity. Life Sci. 1985 Jan 14;36(2):113-9. [PubMed:2857046]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Potentiator
- General Function
- Gaba-a receptor activity
- Specific Function
- GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. Rho-2 GABA...
- Gene Name
- GABRR2
- Uniprot ID
- P28476
- Uniprot Name
- Gamma-aminobutyric acid receptor subunit rho-2
- Molecular Weight
- 54150.41 Da
References
- Nakatsuka I, Shimizu H, Asami Y, Katoh T, Hirose A, Yoshitake A: Benzodiazepines and their metabolites: relationship between binding affinity to the benzodiazepine receptor and pharmacological activity. Life Sci. 1985 Jan 14;36(2):113-9. [PubMed:2857046]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Potentiator
- General Function
- Gaba-a receptor activity
- Specific Function
- GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
- Gene Name
- GABRR3
- Uniprot ID
- A8MPY1
- Uniprot Name
- Gamma-aminobutyric acid receptor subunit rho-3
- Molecular Weight
- 54271.1 Da
References
- Nakatsuka I, Shimizu H, Asami Y, Katoh T, Hirose A, Yoshitake A: Benzodiazepines and their metabolites: relationship between binding affinity to the benzodiazepine receptor and pharmacological activity. Life Sci. 1985 Jan 14;36(2):113-9. [PubMed:2857046]
Drug created on July 31, 2007 07:10 / Updated on August 02, 2018 04:38